Mechanisms of hesperetin in treating metabolic dysfunction-associated steatosis liver disease via network pharmacology and in vitro experiments

Metabolic dysfunction-associated steatosic liver disease (MASLD) poses a global health challenge with limited therapeutic options. Hesperetin, a flavonoid extracted from citrus, exhibits multiple pharmacological properties, but its mechanisms in MASLD-associated lipid metabolism remain unclear. This...

Full description

Saved in:
Bibliographic Details
Main Authors: Wu Yi, Lin Ying, Xu Shan, Su Dan, Yang Hao, Tang Lidan
Format: Article
Language:English
Published: De Gruyter 2025-06-01
Series:Open Medicine
Subjects:
Online Access:https://doi.org/10.1515/med-2025-1215
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850220550922698752
author Wu Yi
Lin Ying
Xu Shan
Su Dan
Yang Hao
Tang Lidan
author_facet Wu Yi
Lin Ying
Xu Shan
Su Dan
Yang Hao
Tang Lidan
author_sort Wu Yi
collection DOAJ
description Metabolic dysfunction-associated steatosic liver disease (MASLD) poses a global health challenge with limited therapeutic options. Hesperetin, a flavonoid extracted from citrus, exhibits multiple pharmacological properties, but its mechanisms in MASLD-associated lipid metabolism remain unclear. This study aimed to explore the mechanism of hesperetin for treating MASLD.
format Article
id doaj-art-2d9ddd9938cf464598bf20976224cd38
institution OA Journals
issn 2391-5463
language English
publishDate 2025-06-01
publisher De Gruyter
record_format Article
series Open Medicine
spelling doaj-art-2d9ddd9938cf464598bf20976224cd382025-08-20T02:07:02ZengDe GruyterOpen Medicine2391-54632025-06-01201202910.1515/med-2025-1215Mechanisms of hesperetin in treating metabolic dysfunction-associated steatosis liver disease via network pharmacology and in vitro experimentsWu Yi0Lin Ying1Xu Shan2Su Dan3Yang Hao4Tang Lidan5Department of Pharmacy, The Second People’s Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, 213164, ChinaDepartment of Pharmacy, The Second People’s Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, 213164, ChinaDepartment of Pharmacy, The Second People’s Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, 213164, ChinaDepartment of Pharmacy, The Second People’s Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, 213164, ChinaDepartment of Pharmacy, The Second People’s Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, No. 68. Gehu Middle Road, Changzhou, Jiangsu, 213164, ChinaDepartment of Pharmacy, The Second People’s Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, 213164, ChinaMetabolic dysfunction-associated steatosic liver disease (MASLD) poses a global health challenge with limited therapeutic options. Hesperetin, a flavonoid extracted from citrus, exhibits multiple pharmacological properties, but its mechanisms in MASLD-associated lipid metabolism remain unclear. This study aimed to explore the mechanism of hesperetin for treating MASLD.https://doi.org/10.1515/med-2025-1215hesperetinmasldil-6-stat3-socs3 signaling pathwaylipid metabolismnetwork pharmacology
spellingShingle Wu Yi
Lin Ying
Xu Shan
Su Dan
Yang Hao
Tang Lidan
Mechanisms of hesperetin in treating metabolic dysfunction-associated steatosis liver disease via network pharmacology and in vitro experiments
Open Medicine
hesperetin
masld
il-6-stat3-socs3 signaling pathway
lipid metabolism
network pharmacology
title Mechanisms of hesperetin in treating metabolic dysfunction-associated steatosis liver disease via network pharmacology and in vitro experiments
title_full Mechanisms of hesperetin in treating metabolic dysfunction-associated steatosis liver disease via network pharmacology and in vitro experiments
title_fullStr Mechanisms of hesperetin in treating metabolic dysfunction-associated steatosis liver disease via network pharmacology and in vitro experiments
title_full_unstemmed Mechanisms of hesperetin in treating metabolic dysfunction-associated steatosis liver disease via network pharmacology and in vitro experiments
title_short Mechanisms of hesperetin in treating metabolic dysfunction-associated steatosis liver disease via network pharmacology and in vitro experiments
title_sort mechanisms of hesperetin in treating metabolic dysfunction associated steatosis liver disease via network pharmacology and in vitro experiments
topic hesperetin
masld
il-6-stat3-socs3 signaling pathway
lipid metabolism
network pharmacology
url https://doi.org/10.1515/med-2025-1215
work_keys_str_mv AT wuyi mechanismsofhesperetinintreatingmetabolicdysfunctionassociatedsteatosisliverdiseasevianetworkpharmacologyandinvitroexperiments
AT linying mechanismsofhesperetinintreatingmetabolicdysfunctionassociatedsteatosisliverdiseasevianetworkpharmacologyandinvitroexperiments
AT xushan mechanismsofhesperetinintreatingmetabolicdysfunctionassociatedsteatosisliverdiseasevianetworkpharmacologyandinvitroexperiments
AT sudan mechanismsofhesperetinintreatingmetabolicdysfunctionassociatedsteatosisliverdiseasevianetworkpharmacologyandinvitroexperiments
AT yanghao mechanismsofhesperetinintreatingmetabolicdysfunctionassociatedsteatosisliverdiseasevianetworkpharmacologyandinvitroexperiments
AT tanglidan mechanismsofhesperetinintreatingmetabolicdysfunctionassociatedsteatosisliverdiseasevianetworkpharmacologyandinvitroexperiments